- Report
- April 2024
- 143 Pages
Global
From €6990EUR$7,950USD£6,023GBP
- Report
- February 2024
- 245 Pages
Global
From €6990EUR$7,950USD£6,023GBP
- Report
- November 2023
- 630 Pages
Global
From €8352EUR$9,500USD£7,197GBP
- Report
- April 2023
- 350 Pages
Global
From €2857EUR$3,250USD£2,462GBP
- Report
- October 2022
- 300 Pages
Global
From €3473EUR$3,950USD£2,992GBP
- Report
- January 2022
- 60 Pages
Global
From €3473EUR$3,950USD£2,992GBP
- Report
- April 2020
- 80 Pages
Global
From €3473EUR$3,950USD£2,992GBP
- Report
- December 2024
- 85 Pages
Spain
From €2616EUR$2,975USD£2,254GBP
€3077EUR$3,500USD£2,652GBP
- Report
- September 2024
- 82 Pages
Japan
From €2616EUR$2,975USD£2,254GBP
€3077EUR$3,500USD£2,652GBP
- Report
- August 2024
- 85 Pages
India
From €2616EUR$2,975USD£2,254GBP
€3077EUR$3,500USD£2,652GBP
- Report
- June 2024
- 182 Pages
Global
From €3363EUR$3,825USD£2,898GBP
€3956EUR$4,500USD£3,409GBP
- Report
- May 2024
- 184 Pages
Global
From €3363EUR$3,825USD£2,898GBP
€3956EUR$4,500USD£3,409GBP
- Report
- May 2024
- 184 Pages
Global
From €3363EUR$3,825USD£2,898GBP
€3956EUR$4,500USD£3,409GBP
- Report
- April 2024
- 180 Pages
Global
From €3363EUR$3,825USD£2,898GBP
€3956EUR$4,500USD£3,409GBP
- Report
- February 2024
- 170 Pages
Global
From €3363EUR$3,825USD£2,898GBP
€3956EUR$4,500USD£3,409GBP
- Report
- February 2024
- 190 Pages
Global
From €3363EUR$3,825USD£2,898GBP
€3956EUR$4,500USD£3,409GBP
- Report
- November 2023
- 77 Pages
France
From €2616EUR$2,975USD£2,254GBP
€3077EUR$3,500USD£2,652GBP
- Report
- October 2023
- 175 Pages
Global
From €3363EUR$3,825USD£2,898GBP
€3956EUR$4,500USD£3,409GBP
- Report
- October 2023
- 138 Pages
North America
From €2989EUR$3,400USD£2,576GBP
€3517EUR$4,000USD£3,030GBP
- Report
- October 2023
- 122 Pages
North America
From €2989EUR$3,400USD£2,576GBP
€3517EUR$4,000USD£3,030GBP

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer.
The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more